Please enable JS

Investors

Press Releases

 
Press Releases
  Date Title View
May 10, 2017
CAMBRIDGE, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences. Bank of America Merrill Lynch 2017 Health Care Conference We...
May 2, 2017
--Company reports Glatopa® 20 mg product revenues of $23 million, a 58% increase over the same period in 2016-- --Ended the first quarter with a strong cash position of $434 million--CAMBRIDGE, Mass., May 02, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter end...
Apr 26, 2017
CAMBRIDGE, Mass., April 26, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Deutsche Bank 42nd Annual Health Care Conference. The presentation is scheduled for Wednesday, May 3rd at 10:00...
Apr 18, 2017
CAMBRIDGE, Mass., April 18, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the first quarter ended March 31, 2017 before the U.S. financial markets open on Tuesday, May 2, 2017.    Manag...
Feb 28, 2017
CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Cowen and Company 37th Annual Health Care Conference. The presentation is scheduled for Tuesday, March 7th at 10...
Feb 21, 2017
CAMBRIDGE, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended December 31, 2016. For the fourth quarter of 2016, the Company reported total revenues of $34.2 million, including $15.8 million in product revenues from Sandoz's sales of ...
Feb 17, 2017
CAMBRIDGE, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), announced today that is has changed the time for its fourth quarter and year end 2016 earnings conference call and webcast. Momenta will now host its conference call and webcast at 8:00 a.m. ET on Tuesday, February 21, 2017.    To access the ca...
Feb 17, 2017
Approval of the Glatopa 40 mg ANDA will be dependent on resolution of Pfizer facility compliance issues Warning letter does not restrict the production or shipment of Glatopa 20 mg CAMBRIDGE, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and...
Feb 17, 2017
CAMBRIDGE, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with...
Feb 7, 2017
CAMBRIDGE, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the fourth quarter and year ended December 31, 2016 before the U.S. financial markets open on Tuesday, February 21, 2...
FirstPrevious
2
...
NextLast
= add release to Briefcase